December 7, 2020 07:02 AM ESTUpdated 06:20 PM

Updated: #ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $2.75B buyout

UniQure may be getting all the ASH attention for hemophilia B, but Pfizer is trying to carve out a niche in hemophilia A.

The pharma …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Up­dat­ed: #ASH20 Best of the Rest: Pfiz­er, Sang­amo launch a dura­bil­i­ty charge at Bio­Marin in hem A; The da­ta be­hind Mer­ck­'s $2.75B buy­out